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 Summary 
Introduction The Electronic Transmission of Prescriptions (ETP) scheme 
has become an important part of the UK Government’s plans for 
modernising the National Health Service1 (NHS). The scheme is scheduled 
to be introduced by the UK Government during 2004 and means that 
prescriptions will pass electronically between General Practitioners (GPs), 
pharmacies and the Prescription Pricing Authority (PPA), eradicating 
paper. ETP pilot schemes were implemented by three consortia during 
2002 and 2003, with a view to deciding which elements of the schemes 
were the most effective. Consortia were named: Pharmacy2U (P2U), 
Flexiscript and TransScript. As part of the evaluation, commissioned by 
the Department of Health (DoH), GPs participating in these pilots were 
questioned by mail as to their opinions both before and after the schemes 
took place. This paper discusses pre and post intervention attitudes and 
highlights areas, identified through statistical testing, where GP’s views 
had changed. 
Method Post-intervention data were available from 26 GPs (19 from P2U, 
3 from Flexiscript and 4 from TranScript). Pre-intervention data were 
available from 129 GPs (54 from P2U, 36 from Flexiscript and 39 from 
TransScript). However, only 9 GPs who completed the post-intervention 
questionnaire also completed the pre-intervention questionnaire.  Those 
who completed both post and pre intervention questionnaires came from 2 
of the consortium , P2U and TransScript, with 6 out of 9 coming from one 
practice (P9) and only 2 coming from TransScript (practices T15 and T4). 
GPs’ pre and post intervention attitudes to ETP were measured on a Likert 
scale where 1 = strongly disagree, 2 = disagree, 3 = neither agree/disagree, 
4 = agree, 5 = strongly agree. 
Conclusions Data for statistical analysis were collected after a 6 month 
trial period. During this time, the ETP pilots were subject to early teething 
problems and there were certain concerns not least of which was the 
increased requirement for competence in computing skills. However, after 
the trial period, there was a generally positive attitude toward ETP. 
Keywords: ETP, general practitioners, attitudes.  
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Introduction 
The implementation of ETP would mean that 500 million prescriptions would 
need to be processed electronically per year by the UK’s National Health 
Service2; this far outweighs the volume currently handled by ETP in other 
countries.  
In early June 2002 ETP trials began at three sites across the UK. Pilots 
officially ended on June 30th 2003. GPs’ opinions about ETP were collected via 
questionnaire both before and after a trial period of 6 months. This paper 
discusses statistical analyses of GP views at the pre and post intervention stages 
of the ETP trail and describes where there is statistical evidence of a change in 
opinion. The questionnaire was constructed jointly between members of the 
Industrial Statistics Research Unit (ISRU), colleagues at the Sowerby Centre for 
Health Informatics at Newcastle (SCHIN) and members of the ETP evaluation 
team at the Manchester School of Pharmacy (MSP). 
Pre and Post Intervention Attitudes to ETP:  
General Attributes 
Viewing all respondents as a whole, Table 1 reports the views for the 
majority of GPs at the pre and post intervention stages of the ETP trial. 
Overall, it is indicated that GPs regarded ETP as being potentially 
beneficial at the pre and post intervention stages in most areas. However, 
on the negative side, the majority of GPs agreed that ETP would increase 
the need for competence with computers and technology. 
Interestingly, the majority of the GPs at the pre intervention stage were 
uncertain as to whether ETP would be a factor in the loss of community 
pharmacies, but after the trial, they did agree that it would be an 
influencing factor. 
Uncertainty (i.e. neither agreement/disagreement) existed as regards 
their views on whether ETP would increase the number of ‘Pricing Pre-
scription Authority’ (PPA) queries, improve patients’ prescription com-
pliance and diminish the potential for disciplinary action arising from 
prescribing errors. 
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On the positive side, before the trial, GPs believed ETP would increase 
the number of pharmacist queries about prescriptions but, after the trial, the 
majority of GPs’ views were reversed. 
Comparison of Pre and Post Intervention Data:  
Paired Samples 
It was our aim to establish if attitudes had changed at the pre and post 
intervention stages. The Sign Test3 and the Wilcoxon Signed Ranks Test3 
were used to compare attitudes to ETP for those 9 GPs who had completed 
questionnaires both before and after the trial. The Sign test merely utilises 
information about the direction of differences within pairs; the Wilcoxon 
Signed Ranks Test is more powerful in that it considers the relative 
magnitude as well as the direction of the differences. Both tests were 
conducted and results compared. Due to only 9 cases being available, 
Monte Carlo estimates of exact significance levels (p-values) were gene-
rated for these statistics to maintain accuracy. The statistical package 
employed was SPSS4. 
For both tests, the questions which showed a difference in response (at 
the 5 % level of significance) were: 
1) I believe ETP will increase the number of pharmacist queries about 
prescriptions  
2) I believe ETP will spread script authorisation throughout the day  
3) I believe ETP will help reduce prescription fraud  
The observed differences in response for this sample of 9 GPs are shown 
in Figure 1. 
After introduction of ETP: 
• Overall, GPs from P2U were less concerned that ETP will increase 
the number of pharmacist queries about prescriptions. Both GPs from 
TransScript were unchanged in their opinion as to whether ETP will 
increase the number of pharmacist queries. 
• Overall, GPs more agreed that ETP will spread script authorisation 
throughout the day. 
• Overall, GPs more agreed that ETP will help reduce prescription 
fraud. 
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Comparison of Pre and Post Intervention Data: 
Independent Samples 
After removal of the 9 GPs who had completed both the pre and post 
intervention questionnaires (and also removing one which had a missing id 
in the post-intervention data), the remaining pre data (120 cases) and post 
data (16 cases) could be viewed as two independent samples. No GPs were 
common to these two groups and no GP within either of the two groups 
had completed both questionnaires.  Since only ‘ordinal’ measurement is 
present in the variables, the Mann-Whitney Test3 was appropriate to 
determine if the two groups were drawn from the same population i.e. to 
establish if pre and post intervention responses differed as regards median 
values. In addition, the chi-squared statistic was also employed to 
determine if the pre and post groups differed as regards proportions in the 
different response categories. Monte Carlo estimates of exact p values 
were again employed for these statistics to maintain accuracy. 
The questions whose replies at both stages were indicated as being 
statistically different at the 5 % level for the Mann Whitney test and/or chi-
squared test are given in Figure 2. The percentages of GPs occurring in 
each of the response categories are given and median response values at 
each stage are also displayed  
There is evidence of a difference in pre- and post- intervention responses 
for the following questions: 
1) I believe ETP will spread script authorisation throughout the day.  
Although the general pattern of responses in the pre and post 
questionnaire is the same, it is observed that, after ETP, more GPs 
agreed/strongly agreed that ETP would spread script authorisation 
throughout the day. 
2) I believe ETP will impair GP/pharmacist relations.  
Before introduction of ETP, the majority of GPs did not think that 
ETP would impair GP and pharmacist relations, after ETP the 
majority of GPs were uncertain. 
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3) I believe ETP will provide concerns with patients who may not want 
to nominate a pharmacy of their choice.  
Before ETP, most GPs agreed that ETP will provide concerns with 
patients who may not want to nominate a pharmacy of their choice, 
after ETP the majority of GPs were uncertain. 
4) I believe ETP will be secure enough to prevent breaches.  
Before ETP, some GPs did not think that ETP would be secure 
enough to prevent breaches. After ETP all of the GPs who completed 
the post intervention questionnaire were either uncertain or agreed 
that ETP would be secure enough. 
5) I believe ETP will provide concerns about breaches of patient 
confidentiality.  
Before ETP, the majority of GPs showed concern as regards 
breaches in patient confidentiality. After ETP, the majority were 
uncertain or disagreed that ETP would provide concerns. 
6) I believe ETP will provide feedback on uncollected prescriptions.  
Before the ETP trial, the majority of GPs agreed that ETP will 
provide feedback on uncollected prescriptions; after the trial, the 
majority of GPs were uncertain. It is also worth reporting that a 
further question (not related to ETP attitude) was also significant. 
The question was  
7) What is your level of awareness of ETP?  
After the ETP trial, all GPs showed awareness. Before implemen-
tation, knowledge was sometimes lacking. 
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Conclusions 
After implementation of the pilot schemes, ETP awareness was shown to 
have increased and, generally, GPs viewed ETP as being potentially 
beneficial. Certain areas of opinion produced a similar reaction both before 
and after the pilot schemes took place. On the human side, GPs felt that 
ETP would reduce patient ordering and waiting time for repeat 
prescriptions, reduce number of patient visits to surgery and increase the 
quality and speed of the repeat prescribing service.  They did not think it 
would give patients less opportunity to interact with their GP or decrease 
the confidence of patients in repeat prescribing. At the business end, the 
majority of GPs felt that ETP would help move to a paperless environment, 
help to reduce prescription fraud, provide feedback on uncollected 
prescriptions and they did not think it would increase their workload or 
decrease their ability to monitor repeat prescribing. 
On the negative side, GPs agreed that ETP would increase the need for 
competence in computers and technology and increase the likelihood of 
repeat dispensing by pharmacists. 
There were, however, still areas of uncertainty which remained after the 
pilot schemes took place. GPs still seemed uncertain as to whether ETP 
would improve patients’ prescription compliance and diminish the 
potential for disciplinary action arising from prescribing errors. 
There were also areas where GPs had become uncertain. After the ETP 
trial, the majority of GPs seemed to be uncertain as to whether ETP would 
impair GP and pharmacist relations whereas at the pre intervention stage 
they did not think the relationship would be affected. After ETP 
introduction, GPs also seemed uncertain about possible patient concerns 
relating to pharmacy nomination, previously they felt that this would be a 
problem. On another positive note, after ETP, the majority of GPs 
disagreed that ETP would increase the number of pharmacy queries about 
prescriptions whereas before they had an opposite opinion.   
For those GPs who completed both pre and post questionnaires, after the 
pilot scheme there was shown to be a more favourable attitude towards 
ETP especially in areas relating to ‘pharmacist queries about pre-
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scriptions’, ‘reduction of prescription fraud’ and ‘the spreading of script 
authorisation throughout the day’. 
It must be borne in mind that at the time of post-questionnaire 
distribution, ETP was in its infancy. This analysis is based on data 
collected after the ETP pilot scheme had been running for only around 6 
months.  Nevertheless, the general attitude towards ETP after this time was 
positive. 
At the end of the scheme in June 2003, over 100,000 prescribing and 
dispensing messages were transmitted between GPs, community phar-
macies and the PPA5. The scheme had been deemed a success and had 
been proven to be technically viable to send and receive secure prescribing 
and dispensing data electronically6.  
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 Before ETP trial After ETP trial 
I believe Electronic Transmission of Prescriptions will: 
Strongly 
disagree/ 
disagree 
Neither 
agree/ 
disagree
Strongly 
agree/ 
agree 
Strongly 
disagree/
disagree
Neither 
agree/ 
disagree
Strongly 
agree/ 
agree 
Increase the workload of GPs.    •   •   
Decrease the confidence of patients in repeat prescribing. •   •   
Increase number of prescribing errors. •      
Decrease GPs ability to monitor repeat prescribing. •   •   
Give patients less opportunity to interact with their GP. •   •   
Impair GP and Pharmacist relations. •    •  
Provide concerns with customers who may not want to nominate a 
pharmacy of their choice. 
  •  •  
Provide concerns about breaches of patient confidentiality.   •    
Increase number of pharmacist queries about prescriptions.   • •   
Increase the likelihood of repeat dispensing by the pharmacists.   •   • 
Increase the number of PPA prescription queries.  •   •  
Diminish the potential for disciplinary action arising from pre-
scription errors. 
 •   •  
Be a factor in the loss of community pharmacies.  •    • 
Increase the need for competence with computers and technology.   •   • 
Spread script authorisation throughout the day.   •   • 
 
 Before ETP trial After ETP trial 
I believe Electronic Transmission of Prescriptions will: 
Strongly 
disagree/ 
disagree 
Neither 
agree/ 
disagree
Strongly 
agree/ 
agree 
Strongly 
disagree/
disagree
Neither 
agree/ 
disagree
Strongly 
agree/ 
agree 
Help move to a paperless environment.   •   • 
Reduce patient ordering time for repeat prescriptions.   •   • 
Reduce the number of patient visits to surgery.   •   • 
Reduce patient waiting time for repeat prescriptions.   •   • 
Help to reduce prescription fraud.   •   • 
Increase the quality of repeat prescribing services.   •   • 
Provide feedback on 'uncollected' prescriptions.   •   • 
Speed up the repeat prescribing process.   •   • 
Reduce errors in the repeat prescribing process.   •   • 
Improve medication management repeat prescribing.   •  •  
Be secure enough to prevent breaches.  •     
Improve patient's prescription compliance.  •   •  
 
Table 1  Views for the majority of GPs at the pre and post intervention stages of the ETP trial 
Note: : Questions which show no opinion did not have a predominant category for the majority of responses. 
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 Figure 2 Differences between GPs at the pre and post intervention stages in 2 independent samples 
C.S.=Chi-squared Test;  M.W.= Mann Whitney Test 
NS=not significant at the 5% level ;  *=significant at ‘table-wide’ 0.05 level after adjustment for multiple comparisons7. 
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